Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.

The long-term follow-up results were published in November 2015.[ 14 ] Even with long-term follow-up and despite an absolute difference in median OS of 14 months, the benefit did not reach statistical significance (62.1 vs. 48.6 months; hazard ratio [HR]: 0.88; 95% confidence interval [CI]: 0.68–1.14; P = 0.3).[ 14 ] However, the biologic progression free survival (HR: 0.73; 95% CI: 0.56–0.94; P = 0.014) and radiologic progression free survival (HR: 0.75; 95% CI: 0.58–0.97; P = 0.030) were significantly longer in the ADT plus docetaxel arm.

also in 111,027 other papers